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Background: Despite enormous progress in elucidating the biophysics of aggregation, no cause-and-effect
relationship between protein aggregation and neurodegenerative disease has been unequivocally established. Here,
we derived several risk-based stochastic kinetic models that assess genotype/phenotype correlations in patients
with Huntington’s disease (HD) caused by the expansion of a CAG repeat. Fascinating disease-specific aspects of HD
include the polyglutamine (polyQ)-length dependence of both age at symptoms onset and the propensity of the
expanded polyQ protein to aggregate. In vitro, aggregation of polyQ peptides follows a simple nucleated growth
polymerization pathway. Our models that reflect polyQ aggregation kinetics in a nucleated growth polymerization
divided aggregate process into the length-dependent nucleation and the nucleation-dependent elongation. In
contrast to the repeat-length dependent variability of age at onset, recent studies have shown that the extent of
expansion has only a subtle effect on the rate of disease progression, suggesting possible differences in the
mechanisms underlying the neurodegenerative process.
Results: Using polyQ-length as an index, these procedures enabled us for the first time to establish a quantitative
connection between aggregation kinetics and disease process, including onset and the rate of progression.
Although the complexity of disease process in HD, the time course of striatal neurodegeneration can be precisely
predicted by the mathematical model in which neurodegeneration occurs by different mechanisms for the
initiation and progression of disease processes. Nucleation is sufficient to initiate neuronal loss as a series of
random events in time. The stochastic appearance of nucleation in a cell population acts as the constant risk of
neuronal cell damage over time, while elongation reduces the risk by nucleation in proportion to the increased
extent of the aggregates during disease progression.
Conclusions: Our findings suggest that nucleation is a critical step in gaining toxic effects to the cell, and provide a
new insight into the relationship between polyQ aggregation and neurodegenerative process in HD.
Keywords: Huntington’s disease, Polyglutamine aggregation, SCA3, Stochastic kinetics model, Cumulative damage,
One-hit model, Nucleated growth polymerization, Nucleation, ElongationBackground
The various disease-specific proteins involved in the dis-
tinct polyglutamine (polyQ) diseases, such as Hunting-
ton’s disease (HD) and spinocerebellar ataxia (SCA)-3
share no sequence homology, except in the polyQ tract.
However, a strong and consistent inverse correlation has
been found between the length of the expansion and the
age of disease onset [1,2].* Correspondence: keizo_sugaya@member.metro.tokyo.jp
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distribution, and reproduction in any mediumIn vitro, aggregation of polyQ peptides follows a sim-
ple nucleated growth polymerization pathway [3].
Nucleated growth polymerization is a two-stage process
consisting of the energetically unfavourable formation
of a nucleus (i.e., nucleation), followed by efficient
elongation of that nucleus via sequential addition of
monomers [4]. Accordingly, the kinetics of the process
feature a long lag time (nucleation lag time) followed
by rapid aggregate growth. The detailed mechanism of
nucleus generation based on polyQ sequences remains
to be understood, however, the kinetic parameters ofd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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repeat length [5].
Recent studies, however, have found multiple pathways
underlying disease-related polyQ protein aggregation [6-
8]. SCA3 is caused by expansion of the polyQ tract in
ataxin-3 [9]. In vitro kinetic studies of ataxin-3 fibrillo-
genesis have revealed an alternative aggregation pathway
in which full-length ataxin-3 has an intrinsic ability to
form amyloid-like fibrils independent of the polyQ tract
[6,10]. Remarkably, pre-fibrillar-like aggregates impli-
cated in the toxicity of several neurodegenerative dis-
eases are formed during the process of ataxin-3
aggregation [6,11]. These observations suggest the pres-
ence of a mechanism whereby expansion of the polyQ
tract accelerates but is not structurally involved in mis-
folding of ataxin-3 into toxic intermediate structures.
One explanation of cell death in neurodegenerative
disorders is that neurons gradually accumulate insults
which ultimately overwhelm cellular homeostasis
[12,13]. One mechanism frequently proposed to cause
cumulative damage is oxidative stress [12,14], in which
an imbalance between the production of reactive oxygen
species and cellular antioxidant mechanisms results in
chemical modifications of macromolecules, thereby dis-
rupting cellular structures and functions. This scenario
is supported by recent work in which the biophysics of
aggregation were associated with the ‘toxic intermediate’
hypothesis, in which an imbalance occurs between the
accumulation of toxic misfolded proteins, such as sol-
uble oligomers/pre-fibrillar aggregates, and cellular pro-
tein quality control mechanisms [11,15].
Soluble oligomeric aggregate of mutant huntingtin
(htt) protein in HD was also found in tissues from
individuals with HD [16]. Some researchers have
sought to advance cumulative-damage hypotheses seek-
ing to explain HD pathogenesis [15,16]. In such sce-
narios, pathologic changes proceed at differential rates,
depending on the length of expansion. This would re-
sult in disease onset when the changes were suffi-
ciently severe to produce a disease symptom. The
extent of expansion would then also govern the rate of
clinical progression. However, it remains unknown
whether the factors governing symptom onset also
control clinical progression of HD. A large prospective
study, assessed using clinical measures, suggested that
polyQ-length had only a subtle effect on the rate of
disease progression [17]. What mechanism of the dis-
ease progression might explain this discrepancy? Ap-
parently, the cumulative-damage hypothesis cannot
explain the exponential relationship between the extent
of expansion and age at onset, nor the effect of
polyQ-length on the progression of HD.
We first present two risk-based stochastic kinetic
models to assess the genotype/phenotype correlations inpatients with polyQ diseases. These models reflect the
different disease pathomechanisms arising via two alter-
native aggregation pathways: the first is the cumulative-
damage model, while the second is the one-hit model,
wherein the one-hit event acts as a constant risk for
neuronal cell damage and the kinetics of neuronal loss
over time exhibit a first-order exponential function [18].
The stochastic appearance of nucleation of mutant htt
proteins in a homogenous cell population over time
could be expressed by a first-order exponential function
[19]. If polyQ aggregate is actually related to disease
pathogenesis, the probability of nucleation is considered
to be a constant risk of neuronal damage regardless of
toxicity because of the rate-limiting process of nucle-
ation. In HD, the repeat-length dependent variability of
age at onset could be reasonably explained by the
length-dependent nucleation of polyQ aggregation kinet-
ics [20]. However, we and others found that one add-
itional polyQ-length independent factor also significantly
contributes to the age at disease onset [20-22]. It is
assumed that age-of-onset (tA) largely reflects a nucle-
ation lag time (tN) and the additional time (addt) due to
the polyQ-length independent factor. One-hit model of
neurodegeneration can be improved with stretched-
exponential decay models, which most easily fit data in
which the rate of death decreases over time, are consist-
ent with multiple populations of cells coexisting, each
with a different constant rate of death [23]. However,
even when we use a stretched-exponential decay model
it alone is not enough to explain the genotype/pheno-
type correlations. By the regression analyses of polyQ-
length versus age-of-onset in patients with HD, we




2) showed the best fit among the models exam-
ined. This is well consistent with the relationship of
tightly coupled processes of nucleation and elongation
during disease progression. Under the assumption that
tN reflects the stochastic appearance of nucleation over
time in a cell population, then it is reasonable to con-
sider that addt reflects the distributed elongation times in
the affected neurons (increased extent of aggregates as
the nucleation events proceed). According to the hypo-
thetical effect of aggregates on neuronal cell (protective
or toxic), we finally derived three different models to
examine whether polyQ aggregation kinetics by a
nucleated growth polymerization mechanism can predict
the effects of polyQ-length on the rate of disease pro-
gression as well.
Methods
Two risk-based stochastic kinetic models for neuronal cell
loss
In inherited neurodegenerative disorders, delayed clin-
ical onset (in which symptoms may not appear for years
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of age-dependent cumulative damage [24]. One predic-
tion of the cumulative-damage hypothesis is that the
probability of cell death will increase over time. How-
ever, Clarke et al. reported that the kinetics of neur-
onal death in many forms of neurodegeneration,
including HD, appeared to be exponential, and in fact
could be better explained by a mathematical model in
which the risk of cell death remains constant (one-hit
model). These models can be expressed by the risk-
based stochastic kinetics as:
dN tð Þ=dt ¼ r tð ÞxN tð Þ ð1Þ
where N is the number of remaining neurons, and r(t)
represents the risk of cell death at age t [18]. Solving
the differential equation of Eq. 1 generates an equation
of exponential function as:





where N0 is the number of neurons before neuronal
cell death begins. The functions for r(t) were substi-
tuted as follows:
cumulative-damage model
r tð Þ ¼ r0exp A t  t0ð Þ½  A > 0ð Þ ð3Þ
one-hit model
r tð Þ ¼ r0 t > t0ð Þ ð4Þ
where r0 represents the initial probability of cell death
and t0 represents the time before neuronal death begins,
and r0e
A corresponds to an increase in risk [18].
PolyQ-length dependence of neuronal cell loss by a
cumulative damage model
In the cumulative-damage hypothesis, it was believed
that there was only a small chance of a cell containing
damage sufficient to initiate apoptosis early in the course
of disease, with a correspondingly low rate of cell loss
during this period. As the amount of intracellular dam-
age increased with time, however, the chance of cell
death also increased. The cumulative-damage model
predicts that the neuronal survival curve will have a sig-
moidal shape (Figure 1A), and that the risk of neuronal
death will increase exponentially over time (Figure 1B)
[18].
Under cumulative-damage conditions, polyQ-length
dependence of the age-of-onset suggests that the risk of
neuronal death increases exponentially with increased
repeat length. Therefore, the relationship between
polyQ-length and age-of-onset would be expected to be










 x xminð Þ½ dx ð5aÞ
where tA is age of disease onset, x is the repeat-length
number, xmin is the minimum repeat length capable of
causing neuronal death, eq-μo is the age of disease onset
with x= xmin, μo = ro/A
* and roe
A* corresponds to an in-
crease in risk with repeat number. Solving the integral
equation of Eq. 5a generates an equation as:
Ln tAð Þ ¼ q  μoexp A x xminð Þ½  ð5bÞ
We initially made the reasonable assumption that the
extent of neuronal cell damage at disease onset would
be nearly identical irrespective of polyQ-length when the
influence of normal aging was ignored. Then, Figure 1C-
E shows an example of the cell-loss kinetics per polyQ-
length based on the cumulative-damage model. If the re-
lationship between polyQ-length and age-of-onset (red
line) could be explained by a sigmoidal function, the
relative time courses of neuronal cell damage for each
polyQ-length would be expected to be described by a
sigmoidal function (Figure 1C, D). As noted, in the sig-
moidal function, the risk of neuronal cell death with
time for each repeat length is precisely reflected by the
correlation between polyQ-length and age-of-onset (red
line in Figure 1E).PolyQ-length dependence of neuronal cell loss by a one-
hit model
In a one-hit model, the kinetics of neuronal degener-
ation—i.e., the ratio N(t)/N0 of viable neurons as a func-
tion of time t—exhibited exponential cell loss decay
(Figure 2A). Exponential kinetics, which can also be used
to describe radioactive decay, indicate that the risk of
cell death is constant (Figure 2B). In this process, the
death of a neuron is initiated randomly in time by a sin-
gle, rare catastrophic event [18].
Under this constant risk condition, the repeat-length
dependence of the age-of-onset suggests that the prob-
ability of the rare event depends on the polyQ-length,
and increases exponentially with repeat number. Thus,
the relationship between repeat-length and age-of-onset
(red line) would be expected to be exponential,
described by using Eq. 2 and Eq. 4 (with t substituted to
x, and N(t)/N0 substituted to tA/a) as:









Figure 1 Schematic representation of the kinetics of cell loss predicted by a cumulative-damage model. (A) Ratio of intact neurons (N(t)/
N0) as a function of time t shows a sigmoidal shape in the cumulative damage model (Eq. 2 and 3). (B) When displayed on a semi-log graph,
neuronal survival curves over time, producing a shoulder shape. (C-E) PolyQ-length dependence of neuronal cell loss by the cumulative damage
model. (C) Assuming that the extent of neuronal cell loss at the onset of disease is identical irrespective of polyQ-length (red line: 30% cell loss is
defined as symptom onset), the relationship between polyQ-length and age-of-onset shows a sigmoidal function (Eq. 5b), and then the time
course of neuronal cell loss for each polyQ-length should be described by sigmoidal kinetics, [as the disease proceeds, t(0.7)! t(0.3)]. (D)
Relationship between polyQ-length and age at an identical ratio of cell loss for each polyQ-length shows a sigmoidal shape. Red line: age at
onset for each polyQ-length [30% neuronal loss, t(0.7)]. (E) Semi-log plots of polyQ-length versus age at an identical ratio of cell loss for each
polyQ-length show that the risks of cell death are represented by the correlation between polyQ-length and age-of-onset (red line)
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equation as:
tA ¼ aexp b x xminð Þ½  ð6bÞ
where xmin* is the minimum repeat length capable of
producing the rare catastrophic event, and a is the age
of disease onset with x= xmin*.
Figure 2C shows an example of the cell-loss kinetics
per polyQ-length under the one-hit model. The relation-
ship between polyQ-length and age of onset (red line)
would be expected to be exponential. During disease
progression, the probability of a one-hit event is distrib-
uted exponentially over time in keeping with theexponential correlation between the repeat-length and
age-of-onset under the constant risk (red line,
Figure 2D, E).
PolyQ-length dependence of age at onset by a nucleation
event
Exponential relationship between polyQ-length and nu-
cleation lag time
An exponential relationship between the extent of ex-
pansion and the nucleation lag time was first proposed
by Perutz et al. based on chemical thermodynamics [5].
The nucleation aggregation theory predicts that the
probability of nucleation is an exponential function of
the free energy of nuclear formation, which is propor-
tional to exp[−ΔGcrit/kT], where ΔGcrit is the critical free
Figure 2 Schematic representation of the cell loss kinetics predicted by a one-hit model. (A) Ratio of intact neurons (N(t)/N0) as a function
of time t shows an exponential decline in the one-hit model (Eq. 2 and 4). (B) When displayed on a semi-log graph, neuronal survival curves over
time, producing a linear line. (C-E) PolyQ-length dependence of neuronal cell loss by the one-hit model. (C) Assuming that the extent of neuronal
cell loss at the onset of disease is identical irrespective of polyQ-length (red line: 30% cell loss is defined as symptom onset), the relationship
between polyQ-length and age of onset shows an exponential function (Eq. 6b), and then the time course of neuronal cell loss for each polyQ-
length should be described by exponential kinetics, [as the disease proceeds, t(0.7)! t(0.3)]. (D) Relationship between polyQ-length and age at
an identical ratio of cell loss for each repeat length shows an exponential shape. Red line: age at onset for each polyQ-length [30% neuronal loss,
t(0.7)]. (E) Semi-log plots of polyQ-length versus age at an identical ratio of cell loss for each polyQ-length show that the slope (risks of cell death)
are preserved during disease progression [t(0.7)! t(0.3)]
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mann’s constant, and T is absolute temperature [5].
Since the addition of each glutamine stabilizes the helix
structure by the formation of another three or four
hydrogen bonds [25], the increase in free energy per
additional repeat is expected to be constant [5]. The
equation therefore predicts that the probability of nucle-
ation rises exponentially with the number of repeats.
The nucleation lag time is defined as the time required
for the formation of a critical number of stable nuclei,
leading to polymerization. If the minimum repeat length
required to form stable nuclei is defined as xmin
+ , thereby,
when the conditions of monomeric nucleus, the nucle-
ation lag time (tN) could be described using anexponential function of repeat-length, as:
tN ¼ Ncri=LCmoRoð Þxexp b x xminþð Þ½  x≧xminþð Þ
ð7Þ
exp b x xminþð Þ½  ¼ exp ΔGþ1=kT þ ΔGþ1=kT½
þ ΔGþ1=kT þ ΔGþ1=kT . . .
where Ncri is the critical number of nuclei required for
polymerization in a given space, L is Avogadro’s number,
Cmo is the bulk concentration of the expanded polyQ
protein monomers, Ro is the initial rate of formation of
stable nuclei, xmin
+ is the repeat length number in the
first structure that is sufficiently stable to form a
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ual repeat, and ΔG+1 is the change of free energy asso-
ciated with one additional repeat.
Sum of square relationship among aggregation time,
nucleation lag time and elongation time
An equation describing polyQ peptide aggregation kin-
etics in vitro by a nucleated growth polymerization
mechanism was described by Chen et al. [3] as:
Δ ¼ 1=2 kþ2knCmo nþ 2ð Þt2 ð8Þ
where Δ is the concentration of monomer that has been
incorporated into polymers, k+ is the forward elongation
rate constant, kn is the equilibrium constant describing
the monomer-nucleus equilibrium, Cmo is the bulk con-
centration of monomers of the expanded polyQ pep-
tides, n* is the critical nucleus (the number of
monomeric units comprising the nucleus), and t is time.
This equation represents the overall pathway of
nucleated growth polymerization. Furthermore, the
results from in vitro kinetic studies suggest that, in this
equation, the only factor dependent on polyQ-length is
the nucleation constant [3,26]. However, nucleation kin-
etics cannot be determined directly through physical
measurement of nuclei because nucleation is a very rare
event and the formed nuclei either quickly collapse to
bulk phase monomer or proceed along the productive
aggregation pathway [4]. Thus, instead of using polyQ
aggregation kinetics to describe the overall pathway of
nucleated growth polymerization, we derived a mathem-
atical model that divides the time required for aggrega-
tion (tagg) into a polyQ-length-dependent nucleation lag
time (tN), and a nucleation-dependent elongation time
(tE). These were based on elongation kinetics obtained
using aggregates of polyQ peptides as a seed; in these
studies, the elongation rates were found to be nearly
identical irrespective of polyQ-length [26-28] and aggre-
gation rates were obtained to be t2-dependent [3,28].
Thus, the relationship could be approximated by Eq. 8
as:
tagg
2  tE2 ¼ tN2 ð9Þ
Mathematical model describing the correlation be-
tween polyQ-length and age at onset




 1=2 ¼ tN ¼ aexp b x xminþð Þ½  ð10Þ
where a* is the nucleation lag time given the minimum
repeat length (= Ncri/LCmoRo). In agreement with a one-
hit model by risk-based stochastic kinetics we demon-
strated in a previous study that apart from SCA3, the
relationship between polyQ-length and age-of-onset inall of the other polyQ diseases examined could be
expressed by a first-order exponential function based on
the repeat-length dependent nucleation of polyQ aggre-
gation kinetics [20]. Assuming that polyQ aggregation is
actually related to disease pathogenesis, we then
hypothesized a mathematical model based on the as-
sumption that the age-of-onset in HD largely reflects a
nucleation lag time and the additional time. Using the
large cohort of HD patients analyzed so far, Langbehn
et al. found that the following exponential function pro-
vided excellent fits to both the mean and variance of the
age of onset as:
tA  h ¼ exp i jx½  ð11Þ
where h, i and j represent independent parameters, and
x is the repeat number [21]. The principal cause of vari-
ability of age at onset is the length of polyQ repeats,
however these findings suggest that the additional factor,
which is independent of the polyQ-length, needs to be
included to refine the model describing the correlation
between polyQ-length and age at disease onset in HD.
We further found that the following relationship be-
tween age-of-onset and the additional time (addt) due to
the polyQ-length independent factor could be a better
fit than Eq. 11:
tA
2addt2
 1=2 ¼ exp i jx½  ð12Þ
Eq. 12 is well consistent with Eq. 10. It is still unclear
whether nucleation itself is toxic to neuronal cell. How-
ever, under the assumption that polyQ aggregation is
related to HD pathogenesis because of the rate-limiting
thermodynamically unfavourable state of nucleation, it is
reasonable to consider that nucleation acts as a constant
risk for neuronal cell damage based on Eq. 6b, Eq. 10,
and Eq. 12. Therefore, Eq. 12 can be expressed as:
tA
2addt2
 1=2 ¼ tN ¼ aexp b x xminþÞð ½ ð13Þ
Distribution function for nucleation lag time in a
homogenous cell population
In Eq. 13, parameter b, which is a constant factor that
depends only on polyQ-length, represents the nucleation
rate with repeat number. Although many factors in this
model are open to change, we can argue that if the en-
vironment remains relatively constant, only a few para-
meters will theoretically vary during disease progression.
This suggests that in a homogenous cell population, the
bulk concentration of the expanded polyQ protein
monomers (Cmo) and the additional time due to the
polyQ-length independent factor are the principal con-
tributors to the underlying pace of neurodegeneration,
while the nucleation rate over time act as the constant
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by the one-hit model (Figure 2) and by a previous study
describing the aggregation behavior of mutant hunting-
tin htt proteins in a homogenous cell population [19].
Colby et al. found that in cultured striatal neurons, the
probability of a cell remaining aggregate-free dropped
exponentially with time at all examined expression levels
of the mutant htt protein. Consistent with this exponen-
tial decay in the number of unaffected cells, a simple
analytical theory exists for the lag time distribution for a
stochastic nucleated polymerization reaction, in which
the lag time of nucleation probability shown an expo-
nential distribution [29]. After a period of nucleation ini-
tiation, the normalized probability distribution function
for nucleation lag time can be simplified to [19]:
P tð Þ ¼ ςexp ςt½  ð14Þ
where ς is the nucleation rate over time. Furthermore,
the probability Pno agg(t) that a given cell will be
aggregate-free at time t will be given by [19]:
Pno agg tð Þ ¼
Z
ςexp ςt½ dt ¼ exp ςt½  ð15Þ
As the quantity of polyQ-expanded proteins in any
one cell is likely to be too low to yield uniform aggrega-
tion behavior, nucleation is a rare event that occurs only
in some cells, leading to the stochastic appearance of
aggregate-containing cells [30]. The derivative equation
describing the uniform aggregation behavior of polyQ-
expanded peptides in vitro (Eq. 8) can be transformed
as:
Δ ¼ 1=2 kþ2knCmo nþ 2ð Þt2 ¼
Z
kþ2knCmo nþ 2ð Þtdt
The sum of the squared association between the times











Thus, if the nucleation rate over time acts as a con-
stant risk for neuronal cell damage in a homogenous cell
population, the probability of aggregate-free neurons or
the ratio of intact neurons (N(t)/N0) as a function of
time t would be expected to decline exponentially, con-
sistent with the stochastic appearance of nucleation. It is
also assumed that nucleation and elongation act con-




2).PolyQ-length dependence of neuronal cell loss by a
stretched-exponential decay model
In a complex and heterogeneous population of cells
involved in a specific brain lesion, multi-exponential
decay functions can appear to provide a better fit for
neuronal cell decay data under a one-hit model,
compared to the assumption of mono-exponential decay.
Indeed, this situation is better represented by
the stretched-exponential function [23], which is a
generalization of the exponential function with one add-
itional parameter, the stretching exponent β, and is
described by Eq. 2 and Eq. 4 as:
N tð Þ=No ¼ exp  ro t  toð Þð Þβ
h i
ð16Þ
The difference between the exponential function and
the stretched-exponential function is schematically
shown in Figure 3A. Figure 3B shows an example of the
cell-loss kinetics per polyQ-length in a stretched-
exponential decay model. Because the value of β is
identical irrespective of polyQ-length, even in a
stretched-exponential decay model, when neurodegen-
eration proceeds with a nucleation event as a constant
risk of neuronal cell damage, the relationship between
repeat-length and the nucleation lag time will be given
by a first-order exponential function as shown in Eq. 13
regardless of the β value (Figure 3C, D). However, in
contrast to the simple exponential function (homoge-
neous constant risk), the parameter of nucleation rate
with repeat number (b) in Eq. 13 will change slightly
during disease progression, thereby reflecting the coex-
istence of multiple population of neurons, each with a
different constant rate of death (compare the slope of
the linear lines in Figure 2E and Figure 3D). Thus, the
additional time in Eq. 13 is not caused by reflection the
coexistence of multiple populations of neurons. As
noted, in the stretched-exponential function, polyQ-
length affects the rate of disease progression more pro-
foundly than the correlation between polyQ-length and
age-of-onset, in inverse proportion to the stretching ex-
ponent, β (Figure 3B-D). These findings suggest that a
stretched exponential decay model alone is not enough
to explain the effects of polyQ-length on the rate of pro-
gression of HD, nor the correlation between the extent
of expansion and age at disease onset.
Striatal neurodegeneration in HD by a nucleated growth
polymerization mechanism
Huntingtin is expressed in all cell types so far tested
[31]. However, the most vulnerable cells to the toxic ef-
fect of the mutation are the neurons in the striatum.
There is a marked selective pattern of neuronal degener-
ation within the striatum. Medium-sized, spiny projec-
tion neurons are disproportionately affected early and
Figure 3 Schematic representation of the cell loss kinetics predicted by stretched-exponential decay models. (A) The stretched
exponential is a generalization of the exponential function with one additional parameter: the stretching exponent, β (1 > β> 0). With β= 1, the
simple exponential function (linearly on semi-log plots) is recovered (Eq. 16). The parameter β depends on the distribution width. (B-D) PolyQ-
length dependence of neuronal cell loss by the stretched-exponential decay model. (B) Schematic representations of the cell-loss kinetics per
polyQ-length in stretched-exponential functions with different β values (β= 1.0, 0.9, 0.8). Assuming that the extent of neuronal cell loss at the
onset of disease (red line: 30% cell loss is defined as symptom onset) is identical irrespective of polyQ-length (B), the relationships between
polyQ-length and nucleation lag time at disease onset, calculated by using Eq. 13 with different β values (β= 1.0, 0.9, 0.8), show a first-order
exponential function regardless of the β values (C). (D) Semi-log plots of polyQ-length versus nucleation lag time at an identical ratio of cell loss
for each polyQ-length (with β= 0.8) show that the slope of linear line (the risk of cell death) slightly changes during disease progression
[t(0.7)! t(0.3)]. Red dotted line: nucleation lag time at disease onset for each polyQ-length [30% neuronal loss, t(0.7)]
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sized aspiny interneurons are relatively spared. Volume
changes of the caudate nucleus accurately predicted the
onset of symptoms and are significantly correlated with
disease progression [32]. Moreover, the age of onset and
CAG repeat length are significantly correlated with the
extent of striatal atrophy [33,34]. Already, 10 years be-
fore the onset of the clinical symptoms, a significant
neuronal loss is observed [35]. The loss of medium-sized
spiny neurons in the caudate nucleus thus reflects the
symptom onset and disease progression. These findings
suggest that the correlation between polyQ-length and
age of HD onset is mainly governed by the time required
for a particular neuronal loss (per Q repeat) in the nu-
cleus and support the legitimacy of modeling approachto predict the time course of neurodegeneration in the
striatum.
From the feature of stochastic aggregation behaviour
(Eq. 15) and the relationship between nucleation lag
time and age-of-onset (Eq. 13), if polyQ aggregation is
actually related to disease pathogenesis, the time
course of neuronal loss in the striatum is expected to
be a better fit with a stretched exponential function
(Eq. 16). However the effects of the polyQ-length inde-
pendent factor (addt in Eq. 13) on neural cell damage
produce subtle differences. Thus, Eq. 16 can be trans-
formed as:
N tð Þ=No ¼ exp  ς tN  tNoð Þð Þβ
h i
¼ F addtð Þ
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where ς* represents nucleation rate-associated constant
described by Eq. 15, tN0 represents the time before a
series of nucleation events appears, and F(addt) repre-
sents the function of the additional time due to the
polyQ-length independent factor.
The sum of square relationship in Eq. 17 (t2 = tN
2 +
addt
2) is well consistent with the relationship of tightly
coupled processes of nucleation and elongation during
disease progression. In some neurons, polyQ aggregates
can be detected prior to the onset of symptom of the
disease. Under the assumption that tN reflects the sto-
chastic appearance of nucleation over time in a cell
population, then it is reasonable to consider that addt in
Eq. 17 reflects the distributed elongation time in the
affected neuron (increased extent of aggregates as the
nucleation events proceed). This allows us to examine
whether polyQ aggregation kinetics by a nucleated
growth polymerization mechanism can reasonably ex-
plain the correlations between genotypes and pheno-
types, including the age of onset and the rate of disease
progression. According to the hypothetical effect of
aggregates on neuronal cell (protective or toxic), we fur-
ther introduced the three different models (Model A-C)
which may potentially describe the time course of neu-
rodegeneration in the striatum. When addt in Eq. 17 was
substituted to tE (elongation time), from the value of tE
2
at the onset of disease (tE-onset
2 ), tE
2 can be varied from 0
to tE-onset
2 at the initiation of neuronal loss.
Model A (tE
2 = 0 at the initiation of neuronal loss): The
kinetics of neuronal cell loss in Model A is schematically
shown in Additional file 1: Figure S1. Nucleation is suffi-
cient to initiate neuronal cell loss in the striatum. The
probability of nucleation over time acts as constant risk
for neuronal damage (gray line), while elongation
reduces the risk against nucleation in proportion to the
increasing extent of aggregates during disease progres-
sion (pink line). The aggregates play a protective role
against polyQ toxicity. Model A can be expressed as:
N tð Þ=No ¼ exp  ς tN  tNoð Þð Þβ
h i
¼ F tEð Þ
¼ 1 ktE2
 β
t2 ¼ tN2 þ tE2 ð18Þ
where k* is the elongation rate-associated constant.
Model B (tE
2 = tE-onset
2 at the initiation of neuronal loss):
The kinetics of neuronal cell loss in Model B is schemat-
ically shown in Additional file 2: Figure S2. PolyQ aggre-
gate itself is required to induce neuronal cell damage,
and toxic to the cell in the striatum. Nucleation is aprerequisite for the formation of toxic aggregates. F(tE) =
tE-onset
2 , constant value.
Model C (0 < tE
2 < tE-onset
2 at the initiation of neuronal
loss): The kinetics of neuronal cell loss in Model C is
schematically shown in Additional file 3: Figure S3. A
specific conformation of polyQ aggregates is required to
induce neuronal cell damage in the striatum. However,
further growth in the extent of the aggregate reduces the
risk of neuronal damage by that specific conformation. F
(tE) (black line) is variable function that depends on the
value of tE
2 at the initiation of neuronal loss. The inter-
mediate product of polyQ aggregates via a pathway of
nucleated growth polymerization is toxic to the cell.Data collection
Clinical data from patients with mutations in relevant
genes, including 308 patients with SCA3 and 312
patients with HD, were derived from earlier reports [36-
40]. Patients with homozygous mutations were excluded.
To elucidate the rate of disease progression in SCA3,
we used correlations between CAG repeat-length and
quantified progression in brain atrophy as visualized by
MR imaging. Abe et al., working with 30 patients with
SCA3, reported significant correlations between the
CAG repeat number and the extent of atrophy (divided
by age at the time of examination) in the pontine teg-
mentum and midbrain [41]. To adjust for individual var-
iations in the size of the skull, the anteroposterior
diameters of the pontine tegmentum and midbrain were
expressed as a ratio to the distance between the nasion
and the inion. These ratios in each SCA3 patient were
subtracted from the grand mean of the same ratio in all
of the control cases as the degree of atrophy of the pon-
tine tegmentum and midbrain. The cited authors found
that there was no significant correlation between age
and size of the anatomic structures of concern (no sig-
nificant effect of normal aging on the atrophy).
To elucidate the effects of polyQ-length on the rate of
disease progression in HD, we used the data of neuro-
pathological change in a post-mortem study, where the
extent of striatum cell loss divided by subject age was
compared with CAG repeat-length [42], and also the
observed relationship between repeat-length and the rate
of functional decline, as assessed by Quantified Neuro-
logical Examination (QNE) scoring administered over
time to patients in a large cohort study [17]. The QNE is
an instrument for quantifying the number and severity
of neurologic findings in HD [43]. Factor analysis of the
QNE items revealed three subscales of highly correlated
items: measurement of chorea, an eye movement sub-
scale, and the Motor Impairment Scale. Motor Impair-
ment scores are highly correlated with striatal atrophy
in the course of disease. CAG repeat-length was
Sugaya and Matsubara Molecular Neurodegeneration 2012, 7:20 Page 10 of 20
http://www.molecularneurodegeneration.com/content/7/1/20significantly associated with the rate of progression of
these clinical measures except chorea [17].
Statistical analysis
We used the UNISTAT 5.6 statistical package for Win-
dows (Unistat) for all analysis. To examine the associ-
ation between age-of-onset and polyQ-length, we
employed linear regression with logarithmic transform-
ation of Eq. 5b and Eq. 13, thus invoking an intrinsically
linear model, as follows:





 1=2 ¼ bxþ Ln að Þ þ bxminþ
þ E ð20Þ
where E represents residual error. Linear regression ana-
lysis was then applied to determine q or addt
2 values by
identifying the points at which the R2 were identical for
a quadratic curve and a linear model with the best fitting
a linear relationship. Models were evaluated using R2
numbers, the F-test, and analyses of residual error to test
whether the assumptions of the regression are reason-
ably satisfied. The small number of individuals with the
shortest and longest repeat sizes precluded rigorous stat-
istical analysis of these patients. Had such an analysis
been conducted, the data would have overwhelmed
other information and thus impacted excessively on the
model parameters.
Estimating the effect of normal aging on neuronal loss in
the caudate nucleus
We initially made the reasonable assumption that the
extent of neuronal cell damage at the onset of disease
was nearly identical irrespective of the polyQ-length
when the influence of normal aging was ignored. If the
time required for a particular neuronal loss in the caud-
ate nucleus for each repeat length reflects a correlation
between repeat length and the age of onset, and if such
a correlation (polyQ-length versus nucleation lag time)
were exponential in nature, eliminating the effect of age
on neuronal loss in the caudate nucleus would be
expected to yield a higher R2 value for the best fit of a
linear relationship between the logarithm of tN at the
age of onset and polyQ size. We first hypothesized that
the loss of neurons in the nucleus was 30% of baseline
number at the onset of disease, irrespective of polyQ
length. Then we examined the gradual effect of age on
neuronal loss. The neuron decreased in a linear manner
by 0.08 ~ 0.16% per year of normal aging, in the interval
20 ~ 30 years of age. From there, we determined individ-
ual R2 values for the correlations between the logarithms
of tN and polyQ size. Recent MR imaging studies of
(19)volumetric and diffusion tensor imaging (providing a
quantitative assessment of the microscopic diffusion
properties of water in living tissue) suggest that age-
related degenerative change, which is thought to reflect
neuronal loss in the caudate nucleus, could be well
described by a linear function [44-46]. Therefore, we
used a linear model.
Results
Correlation between polyQ-length and age of onset in
patients with SCA3
We previously reported a regression analysis of SCA3
disease onset against the CAG repeat lengths in the
ataxin-3 genes of 308 patients, using a logarithmic trans-
formation of age-of-onset (tA), and showed that it fit an
inverted U-shaped curve [20]. This suggests that the re-
lationship might be explained by a cumulative damage
model in a risk-based stochastic kinetics (Figure 1B).
Furthermore, recent in vitro studies of ataxin-3 aggrega-
tion kinetics support the cumulative-damage hypothesis
in the pathogenesis of this disease [6]. We therefore per-
formed a linear regression analysis using Eq. 19 (see
Methods) with natural log-transformed [q –Ln(tA)], and
determined the q value (Figure 4A). The model was vali-
dated by a residual analysis (Figure 4B). We then com-
pared the regression model (pink line) obtained from
Figure 4A to a linear regression of natural log-
transformed tA versus polyQ-length (one-hit model,
black line) (Figure 4C). Apparently, the regression ana-
lysis of the cumulative damage model using Eq. 19
(R2 = 0.583) showed a better fit than those of the one-hit
model (R2 = 0.511) or a simple linear model (tA versus
polyQ-length, R2 = 0.515) (data not shown). As noted,
the residual distribution of the regression by the one-hit
model showed an inverted U-shaped trend (Figure 4D).
The precise values of the parameters of interest, together
with descriptive statistics, were determined by the re-
gression analysis shown in Figure 4A, and the data are
summarized in Table 1.
Progression of illness in SCA3 patients may be expressed
by the cumulative damage
The relationship between polyQ-length and age-of-onset
could be explained by a sigmoidal function. As the kinet-
ics are sigmoidal, the relationship between progression
of illness in SCA3 patients and polyQ-length is expected
to be accurately reflected by the association between
age-of-onset and the repeat-length (Figure 1E). By the
regression model of Figure 4A, the relative risks of neur-
onal cell damage for each polyQ-length were calculated
as shown in Figure 5A. Abe et al., working with 30
patients with SCA3, reported significant correlations be-
tween the CAG repeat number and the extent of atrophy
(divided by age at the time of examination) in the
Figure 4 Correlation between polyQ-length and age of onset in patients with SCA3. A total of 308 patients with expanded CAG repeats in
the ataxin-3 gene were analyzed. (A) Linear regression analysis using Eq. 19 with natural log-transformed [q – Ln(tA)] data against polyQ size
provided the best fit to a linear model (0.0948x – 7.3787) when q= 4.29. The q value was determined by identifying the points at which the R2
were identical for a quadratic curve (red line) and a linear model (black line). (B) Residual analysis of standardized residuals versus standardized
predicted values in the regression model of Figure 4A showed that the residual distribution was normal (i.e., mean= 0). Furthermore, the
scattered points showed no clear pattern, suggesting that variance was constant. (C) Comparison of the regression model obtained from
Figure 4A (pink line) to a linear regression of natural log-transformed tA versus polyQ-length (black line). (D) Residual analysis of standardized
residuals versus standardized predicted values in the regression model of natural log-transformed tA versus polyQ-length showed an inverted
U-shaped trend in the residual distribution (red line)
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ation coefficients were r=−0.88 for CAG size versus the
age-of-onset, and r= 0.768 and r= 0.641 for CAG size
versus the age-adjusted extent of atrophy in the pontine
tegmentum and midbrain, respectively [41]. Here, these
data were re-evaluated using the relative risk of neuronal
cell damage based on polyQ size. The age of diseaseTable 1 Parameters and descriptive statistics derived from th
%patients intercept ±SE slope ±SE
SCA3 95.78 −7.3787 ± 0.424 0.0948 ± 0.00584
HD 98.42 6.6856 ± 0.144 −0.0668 ± 0.00318
SCA3: Ln[q –Ln(tA)] =A
*x+ Ln(μo) – A
*xmin+ E (Eq. 19).
HD: Ln(tA
2 - addt
2)1/2 =−bx+ Ln(a*) + bxmin
+ + E (Eq. 20).
% patients = percentage of all studied patients used to derive the model, SE = stand
mutations in relevant genes, including 308 patients with SCA3 and 312 patients witonset in each of these 30 patients was transformed as 1/
age-of-onset, which corresponds to the rate of atrophy
at the disease onset because of our assumption that the
degree of neuronal damage at disease onset is nearly
identical irrespective of polyQ-length when the influence
of normal aging was ignored (Figure 1C). The correl-
ation between these figures and the relative risk ofe regression analyses of Figures 4A and 6C
addt
2 q R2 F test P
- 4.29 0.474 263.53 < 1.0 x 10-41
217 - 0.588 441.47 < 1.0 x 10-60
ard error, R2 = coefficient of determination. Clinical data from patients with
h HD, were derived from earlier reports [36-40].
Figure 5 Progression of illness in SCA3 patients may be expressed by a sigmoidal function. (A) The relative risk of neuronal damage for
each polyQ-length was derived from the regression model shown in Figure 4A. The risk of neuronal damage with a repeat number of 60 was
defined as 1, and the relative risk of neuronal damage with a repeat number of 65 was calculated as age of onset for 60 repeats/age of onset for
65 repeats. (B-D) Data on the correlation between polyQ-length and quantified changes in brain atrophy as visualized by MR imaging [41] were
re-evaluated using the relative risk of neuronal damage based on polyQ size. (B) The age of onset in patients analyzed by MR imaging was
transformed as 1/age of onset, and correlated with the relative risk of neuronal damage based on polyQ size. Linear correlations between the
relative risks of neuronal damage based on polyQ size and the age-adjusted degree of atrophy in the pontine tegmentum (C) and midbrain (D)
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Figure 5B (r= 0.786, p < 0.0001). Significant correlations
between the relative risk of neuronal damage based on
polyQ size and the age-adjusted degree of atrophy in the
pontine tegmentum (r= 0.766, p < 0.0001) and midbrain
(r= 0.686, p < 0.0001) were observed (Figure 5C and D,
respectively). The similarity between Figure 5B and C is
striking (r= 0.786 versus 0.766), indicating that the rela-
tionship between the progression of atrophy in the pon-
tine tegmentum and polyQ-length is precisely reflected
by the association between age-of-onset and polyQ-
length. As noted, simple linear correlation using Pear-
son’s correlation coefficient showed a slight difference
between polyQ size versus age-of-onset and polyQ size
versus age-adjusted degree of atrophy in the pontine teg-
mentum (r= 0.88 versus 0.768), but the sigmoidal rela-
tionship of the relative risk of neuronal damage to
polyQ-length identified that the correlation was indeedvery high (r= 0.786 versus 0.766). These findings suggest
that disease progression may be kinetically sigmoidal in
nature, and provide support for the cumulative-damage
hypothesis in explaining the pathogenesis of SCA3.
Correlation between polyQ-length and age of onset in
patients with HD
A linear regression analysis of natural log-transformed
tA versus polyQ-length in a total of 312 patients with
HD is shown in Figure 6A (R2 value = 0.532). In contrast
to SCA3, the residual distribution of the regression
model showed a U-shaped trend (Figure 6B). We then
performed a linear regression analysis using Eq. 20 (see
Methods) with natural log-transformed (tA
2 – addt
2)1/2,
and determined the addt
2 value (Figure 6C). The model
was validated by residual analysis (Figure 6D). We also
examined a regression analysis using Eq. 11 by Langbehn
et al. [Ln(tA – h) versus polyQ size] to provide the best
Figure 6 Correlation between polyQ-length and age of onset in patents with HD. A total of 312 patients with expanded CAG repeats in the
HD gene were analyzed. (A) Linear regression analysis of natural log-transformed tA versus polyQ size. (B) Residual analysis of standardized
residuals versus standardized predicted values in the regression model of Figure 6A showed a U-shaped trend in the residual distribution. (C)
Linear regression analysis using Eq. 20 with natural log-transformed (tA
2 – addt
2)1/2 data against polyQ size provided the best fit to a linear model
when addt
2 = 217. The addt
2 value was determined by identifying the points at which the R2 were identical for a quadratic curve (red line) and a
linear model (black line). (D) Residual analysis of standardized residuals versus standardized predicted values in the regression model of Figure 6C
showed that the residual distribution was normal. (E) Linear regression analysis using Eq. 11 (see Methods) with natural log-transformed (tA – h)
versus polyQ-length to provide the best fit to a linear model when h= 13.9. (F) Residual analysis of standardized residuals versus standardized
predicted values in the regression model of Figure 6D showed that the residual distribution was normal
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0.584 (Figure 6E). The model was also validated by re-
sidual analysis (Figure 6F). The regression analysis
made using Eq. 20 provided the best fit to a linear
model when addt
2 = 217, yielding a highest R2 value (=
0.588) among the regression analyses. The principal
cause of variability of age at onset is the length of the
polyQ repeat. However, these findings confirmed the
existence of the additional time due to the polyQ-
length independent factor (addt
2), which significantly
contributes to the age of onset in patients with HD




showed the best fit among the models examined. The
precise values of the parameters of interest, together
with descriptive statistics, were determined by the re-
gression analysis shown in Figure 6C, and the data are
summarized in Table 1.Progression of illness in HD patients can be expressed by
the nucleated growth polymerization mechanism
We derived three different models (Model A-C) which
may potentially describe the time course of neurodegen-
eration in the striatum (see Methods), and examined
whether polyQ aggregation kinetics by a nucleated
growth polymerization mechanism can explain the
effects of polyQ-length on the rate of disease progres-
sion as well.
By longitudinal analysis of caudate volume visualized
by MR imaging in 40 HD gene-positive individuals,
Hobbs et al. found that a difference in caudate volume
between HD patients and controls was evident 14 years
before motor disease onset, at which time the caudate
volume was about 30% lower than the baseline value
[45]. Around 20-30% of neurons within the caudate may
already be lost prior to the onset of any motor related
Sugaya and Matsubara Molecular Neurodegeneration 2012, 7:20 Page 14 of 20
http://www.molecularneurodegeneration.com/content/7/1/20symptoms of the disease [47]. Therefore, we first
hypothesized that neuronal loss in the caudate nucleus
commences 14 years prior to disease onset, and that
30% of neurons within the caudate is decreased from the
baseline at symptom onset. Because there is a markedly
selective pattern of loss for the striatal neurons, we also
first considered that the β value in Eq. 17 and Eq. 18 is
close to 1 (the susceptibility of the affected neurons to
polyQ toxicity is nearly homogenous, mono-exponential
decay [18,48]). Thereby, if the influence of normal aging
was ignored, the slope of linear regression line (Eq. 20)
derived from the regression analysis of the correlation
between polyQ-length and age-of-onset is expected to
be identical during disease progression (Figure 2E). The
time course of neuronal loss in the caudate nucleus can
be estimated by the regression model. We also estimated
the effects of normal aging on neuronal loss in the caud-
ate nucleus (see Methods).
When we used Model A to estimate the effect of age
on neuronal loss in the caudate nucleus (i.e., after the re-
gression model (Figure 6C) was adjusted to reflect a de-
crease with neuronal cell number by 0.15% per year of
normal aging from the age of 25 years), the regression
analysis using Eq. 20 with natural log-transformed tN
values against polyQ size provided the best fit to a linear
model (red arrow in Additional file 1: Figure S1) when tE
2
was 217, yielding the highest R2 value of 0.592 (data not
shown). We calculated the value of tNo in Eq. 18 in ac-
cordance with model A. The value of ς* in Eq. 18 was
obtained for each polyQ-length using the values for tN0
(blue arrow) and tN at the onset of disease (red arrow)
(Additional file 1: Figure S1). The time course of neur-
onal loss for each repeat-length was calculated and then
recalibrated to reflect the influence of normal aging.
When the risk of neuronal damage with a repeat num-
ber of 39 was defined as 1, the relative risk of neuronal
damage per repeat-length is shown in Figure 7A, F and
H. The degree of the effects of polyQ-length on the rate
of neuropathological change (pink circle) is shown to be
a lower than that on the age at disease onset (blue circle)
[42]. Using the time courses of neuronal loss estimated
from each model, we calculated the relative risks of
neuronal damage for each repeat length, by the age at
which there was a 30% neuronal loss (equivalent to age
at disease onset, black circles), and a 65% neuronal loss
(red circles) (Figure 7A, F and H). Because of the differ-
ent models (linear versus exponential), the absolute
values of the risk are different, however the time course
of neuronal loss in Model A precisely reflected the rela-
tionship between the effect of polyQ-length on the age
at disease onset and the effect of polyQ-length on the
rate of neuropathological change (Figure 7A). We used
the predicted LOWESS plots of the QNE scores versus
disease duration for repeat numbers 41, 47 and 53 [17].For comparison, we divided the QNE scores obtained
for 41 repeats or 47 repeats by those obtained for 53
repeats (Figure 7B-E, G and I). Similarly, the estimated
percentage of neuronal losses versus disease duration in
each model for 41 repeats or 47 repeats was divided by
that for 53 repeats (Figure 7B-E, G and I). The estimated
rate of progression of neuronal losses in Model A for 41,
47 and 53 repeats precisely reflected the association be-
tween polyQ-length and clinical progression in HD
patients (Figure 7B).
We also calculated the time course of neuronal loss in
Model A when neurons losses account 20, 40 or 50% of
baseline number at the onset of disease. Similarly, the
estimated time courses of neuronal loss also precisely
predicted the effects of polyQ-length on the rate of
neuropathological change (data not shown). However, by
comparing of the progression of QNE score against dis-
ease duration, we found that the estimated progression
of neuronal loss in Model A precisely reflected the asso-
ciation between polyQ-length and clinical progression
when we hypothesized neuronal loss account 20 or 30%
of baseline at disease onset (Figure 7B-E).
Similarly, we calculated the time course of neuronal
loss in Model B and Model C when neurons losses ac-
count 30% of baseline number at the onset of disease
(Additional file 2: Figure S2, Additional file 3: Figure S3).
In contrast to Model A, the time course of neuronal loss
in Model B and Model C cannot reflect the effects of
polyQ-length on the neuropathological change
(Figure 7F, H), nor the association between polyQ-length
and clinical progression assessed using QNE scoring
(Figure 7G, I). In Model B and Model C, polyQ aggre-
gate itself is thought to be required to initiate neuronal
loss, and nucleation is a prerequisite for the formation
of toxic aggregates. The time course of neuronal loss in
Model C was calculated when tE
2 at the initiation of
neuronal loss = 100.
The rate of neuronal loss estimated using the mathem-
atical model (Eq. 18) can precisely predict the correl-
ation between repeat length and age of onset, as well as
the association of repeat length with the rate of disease
progression. These results suggest that nucleation is suf-
ficient to initiate neuronal loss (Model A), and that
around 20-30% of neurons within the caudate nucleus
are lost at the onset of disease. However, our results can-
not deny the possibility that a specific conformation of
polyQ aggregates is required to induce neuronal cell
damage (Model C). In Model C, tE
2 at the initiation of
neuronal loss is variable (0 < tE
2 < 217). Then, Model C is
nearly identical to Model A when the value of tE
2 at the
initiation of neuronal loss gets closer to 0.
The precise determination of the β value will be
required for a large cohort-based longitudinal study in
patients with the various CAG repeat length. Using
Figure 7 Validation of the time course of neuronal loss in the caudate nucleus using Model A-C. (A, F, H) When the risk of neuronal
damage with a repeat number of 39 was defined as 1, the relative risks of neuronal damage were obtained from the correlation of polyQ size
versus post-mortem striatal cell loss divided by subject age (pink circles) or by the correlation of polyQ size versus 1/reciprocal age at onset (blue
circles) [42]. Using the time courses of neuronal loss estimated from each model, the relative risks of neuronal damage per polyQ-length were
calculated by the age at 65% neuronal loss (red circles) and 30% neuronal loss (black circles) in a similar manner. (B-E, G, I) The predicted
LOWESS plots of QNE scores versus disease duration for 41, 47 and 53 repeats were used [17]. The data on the estimated time courses of
neuronal loss in each model were transformed to show the relationship between percentage of neuronal loss and disease duration from age at
onset for patients with 41, 47 or 53 repeats. Here, the QNE scores and the percentage neuronal losses in the caudate nucleus against disease
duration for 41 repeats or 47 repeats were divided by those for 53 repeats. Because QNE score is lineally increased by longer polyQ repeats
during disease progression [17], we investigated the linear correlation between [(QNE scores at 41 repeats/QNE scores at 53 repeats)  (neuronal
losses at 41 repeats/neuronal losses at 53 repeats)] and [(QNE scores at 47 repeats/QNE scores at 53 repeats)  (neuronal losses at 47 repeats/
neuronal losses at 53 repeats)] (QNE[41/53]/NL[41/53] versus QNE[47/53]/NL[47/53]). We calculated the time courses of neuronal loss when
neurons number account 30% of baseline at disease onset (B, G, I). In Model A, we also calculated when neurons number account 20 (C), 40 (D)
or 50% (E) of baseline at disease onset
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expected to be close to 1 or not. We examined the time
courses of neuronal loss in the caudate nucleus using
different values for the β parameter (β= 0.95, 0.9 and
0.8), and compared our results to the effects of polyQ-
length on the rate of neuropathological change
(Figure 7A). The relative risks of neuronal damage for
each repeat-length were calculated in a manner similar
to that shown in Figure 7A for the age at 30% neuronal
loss and 65% neuronal loss (data not shown). Our results
suggest the range of β value falls in a range of
1 > β > 0.95, and suggest that the susceptibility of the
affected neurons to polyQ toxicity in the caudate nu-
cleus is nearly homogeneous in the early and middle
phases of HD. These results are well consistent with the
reports by Miller et al. [49] using an automated micro-
scope that tracked thousands of primary cultured striatal
neurons individually over their entire lifetime. They
found that until 6 days after the transfection of mutant
HD gene, the kinetics of cell death showed a constant
risk. This duration corresponds to the early and middle
phases of the disease.
The function described by Langbehn et al. (Eq. 11)
[21] also showed the excellent fit to the data obtained
from the correlation between polyQ-length and age of
onset in patents with HD (Figure 6E). However, using
the regression model shown in Figure 6E, we found that
the simple sum of relationship [t= tN+ addt (h)] could
not predict the effects of polyQ-length on the rate of
disease progression in HD (data not shown).
Discussion
Increased understanding of various polyQ diseases has
revealed some common mechanistic features attribut-
able to the existence of expanded polyQ tract per se
[1,2,50]. However, recent studies have found multiple
pathways underlying disease-related polyQ protein
aggregation [6-8,51]. Tissues from individuals with HD
contain mixtures of both elongation-competent and
elongation-incompetent polyQ aggregates, suggesting
the presence of multiple aggregates differing in both
structure and toxicity [52]. Therefore, we must critic-
ally question whether alternative aggregation pathways
contribute to possible differences in the mechanisms
of polyQ disease pathogenesis.
Using polyQ-length as an index, we have here eluci-
dated a relationship between aggregation pathways and
disease onset or progression, and also an association be-
tween age at disease onset and rate of disease progres-
sion. Although disease mechanisms in polyQ disorders
share unifying features, our modeling approach based on
clinical data suggests that two different mechanisms may
be involved in the pathogenesis of these conditions. Any
quantitative connection between the relative risk of celldeath for different repeat-lengths (as derived from the
regression model for SCA3, Figure 5A), and a toxic ef-
fect of intermediate ataxin-3 aggregates, remains un-
determined. However, our finding that correlations
between genotypes and phenotypes, including both age
at disease onset and rate of disease progression, could be
reasonably explained using two distinct kinetic models
corresponding to alternative pathways of aggregation,
strongly support a central role for polyglutamine-
mediated aggregation in disease pathogenesis.
Our results suggest that the time course of neurode-
generation in SCA3 may be represent by the cumulative
damage model. There are many failure laws correspond-
ing to cumulative damage for aging systems, and the
most famous one in biology is the Gompertz law with
exponential increase of the failure rates with age (Eq. 3),
which is observed for many biological species including
humans and is usually applicable within some age win-
dows rather than the entire range of all possible ages
[53,54]. The correlation between polyQ-length and age
of onset in patents with SCA3 showed the best fit with
the Gompertz function among the models examined
(Figure 4). The other model describing the cumulative
damage might be possible to be a better fit than the
Gompertz function. However, it is required for a large
cohort longitudinal study to determine whether such a
model also show a better fit to the association between
polyQ-length and the rate of disease progression. We
also acknowledge that an essential condition for a cumu-
lative damage model is that the rate of neurodegenera-
tion is accelerated over years, but this was not shown in
the present study. Compared to the other polyQ dis-
eases, such an acceleration of disease progression in
SCA3 was reported using clinical measure, but this study
lack the relation to polyQ-length [55]. Very little longi-
tudinal neuroimaging data are available for SCA3, and
no study has examined the extent of neuronal cell dam-
age at the onset of disease or its relationship (if any) to a
particular brain structure. Further study are warranted,
such a detailed longitudinal study that considers polyQ-
length, including the effects of normal aging and clinical
manifestations; this should confirm the sigmoidal kinetic
nature of disease progression and clarify whether atro-
phy of the pontine tegmentum can be used as a bio-
marker of disease progression in SCA3.
In a one-hit model of neurodegeneration by Clarke
et al., the death of a neuron is initiated randomly in time
by a single, rare catastrophic event and the death of any
given cell is independent of that of any other cell
[18,56]. They further found that the one-hit model of
neurodegeneration can be improved with stretched ex-
ponential decay models, which most easily fit data in
which the rate of death decreases over time, are consist-
ent with multiple populations of cells coexisting [23].
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atal neurodegeneration in HD consists with the one-hit
model. In our model, polyQ-length dependent nucle-
ation is considered to be a one-hit event. However, one
important difference to the one-hit model exists. Using
polyQ-length as an index, we demonstrated that even
when we used a stretched-exponential decay model it
could not fully explain the correlation between polyQ-
length and age-of-onset in patients with HD, nor the
association of polyQ-length with the rate of disease pro-
gression (Figure 3). By the regression analysis shown in
Figure 6 and the modeling approach for the disease pro-
gression shown in Figure 7, we found that in addition to
the nucleation event, the polyQ-length independent fac-
tor (addt in Eq.13 and 17) significantly contributes to the
progression of neurodegenerative process. The data,
moreover, suggest that its protective role against polyQ
toxicity. Under the assumption that tN in Eq. 17 reflects
the stochastic appearance of nucleation over time in a
cell population, then it is reasonable to consider that the
polyQ-length independent factor reflects the distributed
elongation times in the affected neurons because of the
consistent figure of Eq. 10 and 13 and the relationship of
tightly coupled processes of nucleation and elongation
during disease progression. This allows us to examine
whether polyQ aggregation kinetics by a nucleated
growth polymerization mechanism could reasonably ex-
plain the genotype/phenotype correlations. However, the
other scenario might be possible. For example, if dying
neurons released a cyto-protective substance such as a
neurotrophic factor into their environment and its pro-
tective effect can be expressed by the sum of square rela-
tionship as t2 = tN
2 + addt
2 (Eq.17), then the concentration
of that factor will increase as more neurons affected,
causing a concomitant decline in the risk of cell death.
The functions in Eq. 18 (Model A) predict that the sto-
chastic appearance of nucleation of mutant htt proteins
acts as the constant risk of neuronal cell death over
time, while elongation reduces the risk against nucle-
ation in proportion to the increased extent of the aggre-
gates during disease progression. Aggregate formation
occurs via intrinsic properties of misfolded proteins, and
is influenced by the environmental factors. Anyway,
these scenarios suggest that although the initiation of
the neurodegenerative process occurs randomly in time
as a series of independent events for each neuron, the
progression of the neurodegenerative process may be
influenced by the other cells.
Using an automated microscope that tracked thou-
sands of primary cultured striatal neurons individually
over their entire lifetime, Miller et al. found that a spe-
cific monomeric conformer of the mutant htt protein
strongly predicted neuronal cell death, and that increas-
ing polyQ length preferentially increased the abundanceof this conformer [49]. Nagai et al. analyzed the struc-
tural changes among purified polyQ protein in vitro and
found that expanded polyQ proteins undergo a conform-
ational transition to a cytotoxic β-sheet-dominant struc-
ture in the monomeric state [57]. In contrast to
conventional models of nucleated growth polymerization,
the in vitro aggregation kinetics of polyQ peptides show
that the critical nucleus—the number of monomeric
units comprising the nucleus—is equal to 1, suggesting
that the rate-limiting nucleation process of polyQ aggre-
gation is the folding of the mutated protein monomer
[3]. Our modeling is compatible with the in vitro-derived
aggregation kinetics of polyQ peptides, and demonstrates
that nucleation is sufficient to initiate neuronal loss in
the striatum. Taken together, these findings strongly sug-
gest that nucleation is a critical step in gaining toxic
effects to the cell. However, we cannot deny a principal
pathogenic role for soluble oligomeric aggregates of mu-
tant htt proteins, if they are made of a small number of
monomeric units via a pathway of nucleated growth
polymerization. In this case, we would expect the kinetics
of cell death to closely fit Model A (corresponds to the
situation where Model C is nearly identical to Model A
when the value of tE
2 at the initiation of neuronal loss gets
closer to 0).
Arrasate et al. found that in cultured striatal neurons,
among cells with comparable expression levels of the htt
fragment, those that formed inclusion bodies were less
likely to die than those that did not. The author sug-
gested that inclusion body formation reduces the risk of
neuronal death by decreasing the levels of toxic mono-
meric forms of mutant htt [58]. Our results well support
these findings, although in our mathematical model, the
risk of neuronal cell death decreases in proportion to
increases in the extent of aggregates, rather than the for-
mation of inclusion bodies itself. Thus, at least in the
caudate nucleus, the pathological cellular effects of HD
likely accrue via a pathway of nucleated growth
polymerization, as represented by the mathematical
model given in Eq. 18.
Toxic soluble oligomer/pre-fibrillar aggregates have
been implicated in many other neurodegenerative condi-
tions, including Alzheimer’s disease and Parkinson’s dis-
ease [11,59,60]. If, such aggregates play a major role in
disease pathogenesis via a cumulative damage mechan-
ism, we would expect that the time courses of neuronal
cell damage would fit a sigmoidal function, as shown in
the case of SCA3 (Eq. 3). However, for example, recent
positron emission tomography studies of Parkinson’s dis-
ease have invariably shown exponential declines in
nigrostriatal dopamine function over time [61-63], con-
sistent with a one-hit mechanism of neurodegeneration.
A heterogeneous population of soluble oligomeric spe-
cies of α-synuclein (which is believed to be a major
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been identified as forming via different aggregation path-
ways [64]. If toxic soluble oligomers occur via a pathway
of nucleated growth polymerization, we would expect
the kinetics of neuronal cell damage to closely fit an ex-
ponential function, as shown in the case of HD (Eq. 18).
We propose, therefore, that at least these two distinct
kinetic models, which are both based on the aggregation
of misfolded proteins, could explain the gain of toxic
functions in neurodegenerative disorders.Conclusions
Although disease mechanisms are superficially attribut-
able to the existence of expanded polyQ per se, our
findings suggest that two different mechanisms, reflect-
ing alternative pathways of aggregation, may be
involved in the pathogenesis of polyQ diseases. We suc-
cessfully derived a quantitative connection between
polyQ aggregation and neurodegenerative processes in
HD, including the time of disease onset and the pro-
gression of illness in HD patients. Finally, we developed
the mathematical model by which the time course of
striatal neurodegeneration in HD can be precisely pre-
dicted. The results of our modeling approach suggest
that neurodegeneration occurs by different mechanisms
for the initiation and progression of disease processes.
The repeat-length dependent one-hit event acts as a
constant risk for neurodegeneration, while the repeat-
length independent factor plays a significant protective
role against the risk by the on-hit events in the progres-
sion of HD. Their relationship could be expressed by
the sum of square relationship. These processes can be
well explained by the nucleated growth polymerization
mechanism of polyQ aggregation, providing a new
insight into the framework for relating aggregation kin-
etics with molecular mechanism underlying neurode-
generative process.Additional files
Additional file 1: Figure S1. Schematic representation of the
functions of Model A (Eq. 18) with β= 1. Gray line reflects the
probability distribution function for nucleation lag time (tN) against the
number of unaffected cells (N(t)/N0) shows a first-order exponential
function. Pink line represents the time course of neuronal loss in Model
A. Black line: the function of elongation time versus N(t)/N0 [F(tE) in
Eq. 18]. The co-relational model of polyQ-length versus tN0 (blue arrow)
was derived from the regression model of the correlation between
polyQ-length and age of onset in patients with HD (Figure 6C). After
elimination of the estimated effect of normal aging on the caudate
nucleus, the regression analysis of polyQ-length versus Ln(tN at disease
onset) provided the highest R2 value to the linear model (red arrow).
Slope of the gray line (ς* in Eq. 18) can be obtained for each
polyQ-length using the values for tN0 and tN at disease onset. Slope of
the black line was obtained from the values for tE
2 at the initiation of
neuronal loss (= 0) and tE
2 at disease onset (= 217).Additional file 2: Figure S2. Schematic representation of the
function of Model B (Eq. 17 with addt substituted to tE, and β= 1).
Gray line reflects the probability distribution function for nucleation lag
time (tN) against the number of unaffected cells (N(t)/N0) shows a first-
order exponential function. Pink line represents the time course of
neuronal loss in Model B. The elongation time (tE) is constant value
(tE
2 = 217). When we used Model B to estimate the effect of age on
neuronal loss in the caudate nucleus (i.e., after the regression model
(Figure 6C) was adjusted to reflect a decrease with neuronal cell number
by 0.09% per year of normal aging from the age of 25 years), the
regression analysis using Eq. 20 with natural log-transformed (tA
2 – tE
2)1/2
values against polyQ size provided the best fit to the linear model (red
arrow) when tE
2 was 217, yielding the highest R2 value of 0.591 (data not
shown). We calculated tN0 in Eq. 17 (blue arrow) in accordance with
model B. Then, the slope of gray line (ς* in Eq. 17) can be obtained for
each polyQ-length using the values for tN0 and tN at disease onset.
Additional file 3: Figure S3. Schematic representation of the
function of Model C (Eq. 17 with addt substituted to tE, and β=1).
Gray line reflects the probability distribution function for nucleation lag
time (tN) against the number of unaffected cells (N(t)/N0) shows a
first-order exponential function. Pink line represents the time course of
neuronal loss in Model C. The elongation time (tE) at the initiation of
neuronal loss is variable (0 < tE
2 < 217). Here, the time course of neuronal
loss in Model C was calculated when tE
2 at the initiation of neuronal
loss = 100. When we used Model C to estimate the effect of age on
neuronal loss in the caudate nucleus (i.e., after the regression model
(Figure 6C) was adjusted to reflect a decrease with neuronal cell number
by 0.13% per year of normal aging from the age of 25 years), the
regression analysis using Eq. 20 with natural log-transformed (tA
2 – tE
2)1/2
values against polyQ size provided the best fit to the linear model (red
arrow) when tE
2 was 217, yielding the highest R2 value of 0.593 (data not
shown). We calculated tN0 in Eq. 17 (blue arrow) in accordance with
model C. Then, the slope of gray line (ς* in Eq. 17) can be obtained for
each polyQ-length using the values for tN0 and tN at the onset of disease.
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